Address: Rosenkavalierplatz 12, 81925 München,Germany
Tel: +49 (0)89 – 8 59 50 96
Web: http://www.bvma.de/
The “Bundesverband Medizinischer Auftragsinstitute” (BVMA) was founded in July 1991 in order to represent CROs (Contract Research Organisations) which are based in Germany or German speaking countries. The BVMA is based in Munich. As of April 2009 there are 26 member companies of the Association, operating in the field of clinical research at a national as well as international level.Companies (legal entities) offering services in the context of clinical research (such as planning/conducting/analysing clinical trials; quality assurance; laboratory services; regulatory affairs of medicinal products / medical devices) may become members, provided they have been operating commercially for at least two years and they meet the quality prerequisites which have been defined by the BVMA.In order to make sure that each member maintains the requirements of high quality, system audits are carried out every three years. The general meeting appoints an external organisation to carry out this task. This self-imposed measure guarantees continued high standards of all the member companieThe current President of the BVMA is Dr Dagmar Chase.
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, critiques the draft EU Pharma Regulation…
Merck KGaA’s Marco Rauland and Kaushal Kishore examine how artificial intelligence and machine learning can best be applied in pharmaceutical pricing and market access. Noting the significant uptake of such…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, launches a critique of current pharmaceutical…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Germany-based pharma and healthcare services group Fresenius has had its share of challenges. After the group’s dialysis division, Fresenius Medical Care (FMC), was hit with a high rate of COVID-19…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
At the recent World Economic Forum in Davos, Chair of the Executive Board and CEO of Merck, Belén Garijo, speaking in a session on workforce transformation in the digital era,…
In response to a looming deficit of EUR 17 billion, Germany’s new Financial Stabilization of Statutory Health Insurance System Act (GKV-Finanzstabilisierungsgesetz, or GKV-FinStG) is aimed at containing costs in the…
The latest from German pharma, including Merck KGaA’s increased gamble on external innovation, Bayer’s focus supply chain stability, CatalYm’s EUR 50 million series C financing and Boehringer Ingelheim’s deal with…
A roundup of some of the biggest recent stories from German pharma, including the latest on beleaguered Bayer CEO Werner Baumann, Merck KGaA’s latest investments in France and Germany, and…
A snapshot of Germany, one of the European pharma hotspots featured in PharmaBoardroom’s latest report, InFigures: European Pharma Hotspots 2022. With the largest market value in Europe, Germany remains at…
The latest from German pharma, including Bayer’s 2021 financial results, the country’s plan to spend $3.14 billion on vaccine capacity to cover Covid-19 outbreaks until 2029, and Boehringer Ingleheim’s case…
See our Cookie Privacy Policy Here
